NeuroDerm Files for a Proposed $65M NASDAQ IPO נוירודרם הגיש תשקיף לגיוס של כ-65 מיליון דולרים בנאסד"ק

Following the trend of Israeli biotechs going public, Rehovot-based NeuroDerm has filed with the SEC to raise $65 million in an initial public offering. The company plans to list on the NASDAQ under the ticker symbol ‘NDRM’.

Jefferies LLC and Cowen & Company, LLC are the joint bookrunners on the deal. No pricing terms have yet been disclosed. News of the filing has come within only a month of the company’s latest financing round of $16 million.

NeuroDerm is a clinical-stage pharmaceutical company developing formulations and new administration methods to treat moderate to severe Parkinson’s disease. The company has developed a line of levodopa/carbidopa product candidates administered through small belt pumps that deliver a continuous, controlled dose of drug. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot.

Read the SEC Filing.

Read about the IPO filing in Hebrew at Globes.

Comments

comments